Navigation Links
TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
Date:9/10/2007

e patient and his or her physician to confirm whether the protocols that appeared in the search results are an appropriate treatment option. Patients can also save their searches and send them via email to themselves or others for their personal use.

Bridging the Clinical Trial Knowledge Gap

These combined features allow users to continue to bridge the gap between patients seeking treatment options through clinical trials and the researchers who provide those clinical trials.

Although cancer clinical trials offer access to state-of-the-art care - and the potential for the development of more effective cancer treatments - the vast majority of cancer patients are unaware that clinical trials are a treatment option. Yet, data from a study of cancer survivors conducted by the Coalition and Northwestern University found that most patients (87 percent) would have considered enrolling had they known about the option at the time of their diagnosis. The findings also showed that most (84 percent) of those survivors who did enroll in a clinical trial were encouraged by their physician to participate.

"The combined power of two leading cancer organizations can help bridge these serious gaps in cancer clinical trial awareness and participation," said Robert L. Comis, M.D., Coalition president and chairman. "The data clearly underscore that it is crucial that cancer patients - and their physicians - are aware of clinical trial availability. With this new TrialCheck service, we can work with the American Cancer Society to reverse these enrollment trends and give patients access to information that can inform and facilitate discussion with their physician."

"This new service will help the American Cancer Society put clinical trial information into the hands of patients," said Richard. C. Wender, M.D., national volunteer president of the American Cancer Society. "Making the information easy to access and providing it in a way that supports the discussi
'/>"/>

SOURCE Coalition of Cancer Cooperative Groups
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
11. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BETHESDA, Md. , Sept. 16, 2014 ... a biotechnology company developing DCVax® personalized immune therapies for ... the first product to receive formal designation as a ... to Medicines Scheme" (EAMS) launched in the UK in ... a 2-step process for early access approval under the ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Henry Schein To Present At The Leerink Partners Services Roundtable 2
... DIEGO, Feb. 29, 2012  Polaris Group (Polaris) today announced ... Phase 1 clinical trial evaluating its lead cancer therapeutic, ... emphasis on leukemia, lymphoma and sarcoma cancers. These three ... in the pediatric population. Patients with advanced ...
... Md., Feb. 29, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) (NW ... Ph.D., MA, MBA, will be presenting at the Cancer ... pm ET on Wednesday, February 29, 2012, in Boston, Massachusetts ... (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ...
Cached Medicine Technology:Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 2Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 3NW Bio to Present at the Cancer Immunotherapy Summit 2NW Bio to Present at the Cancer Immunotherapy Summit 3NW Bio to Present at the Cancer Immunotherapy Summit 4
(Date:9/16/2014)... (PRWEB) September 16, 2014 Cloud ... Live Streaming (HLS) & UStream API’S to serve m3u8 ... wonderful feature for broadcasting live video events with hundreds ... apps. , The App Builder is known for making ... android, iOS, BlackBerry and Windows 8 and already over ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new ... with a bad heart condition. , Clients who have ... insurance if they compare quotes. Most agencies will insure ... on the actual and past medical condition. , ... heart attacks in the past, his or her chances ...
(Date:9/16/2014)... An experimental positron emission tomography (PET) tracer is effective ... still alive, according to a case study conducted at ... at Molecular Neuroimaging (MNI) LLC in New Haven, and ... . , Specifically, the study results suggest that an ... to latch onto a protein called tau that accumulates ...
(Date:9/16/2014)... predict a man,s risk of getting prostate cancer after ... analysis of the cancer,s genetic biomarkers, reported in ... and Biomedical Innovation,s Dr Jyotsna Batra and Distinguished Professor ... large consortia of research hubs around the world, said ... in 80,000 men. , "It,s the largest analysis of ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 An experimental ... concussion-related brain disease while a person is still alive, ... School of Medicine at Mount Sinai, and at Molecular ... 16 in the journal Translational Psychiatry. , Specifically, the ... [18 F]-T807, which is designed to latch onto a ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4
... province said the SARS virus could be stopped and could ... health department, said the average daily new cases had dropped ... He gave this assurance as he was treating three foreigners, ... were infected.// ,He said the number of cases of ...
... 2003 Annual Meeting of the American Association for Cancer Research, ... means of cancer prognosis than measuring body mass index and ... the measures for detecting breast cancer are perfect, says lead ... ,But, he says that levels of leptin which signals ...
... St Mary's Hospital, Manchester, UK, has shown that family history of ... breast cancer. A survey of a group of 99 women under ... third of them had a strong history of either breast or ... cancer, 44 per cent were found to carry// mutations in the ...
... Kansas have now studied a new electrical device,that ... victims of Parkinson's disease.,This new treatment involves implanting ... of life for Parkinson's patients. This,electrical device helps ... the,signals that otherwise cause disabling tremor. The researchers ...
... long time now a lot of health experts that to ... has been advised we should,drink at least eight 8-ounce glasses ... Researchers from Center for Human Nutrition at the,University of Nebraska ... keep ourselves hydrated.// A group of 27 male volunteers were ...
... the A & A Pain Institute in St Louis, Missouri(A ... of pain), have,found that an anticonvulsant drug levetiracetam brings dramatic ... seven patients between 39 and 67 who had,severe nerve pain ... on,the nerve, analgesic drugs were not effective in relieving the ...
Cached Medicine News:
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The LightCycler 2.0 System is the ... Applied Science. This new instrument offers six ... 530, 560, 610, 640, 670, and 710nm. ... cooling by air and working with glass ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
Medicine Products: